Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the approved indication for KRYSTEXXA plus methotrexate, an immunomodulator commonly prescribed by rheumatologists. “Horizon has invested substantially in research and development efforts to improve the safety and efficacy of KRYSTEXXA in the various patient populations who are affected

Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland. When completed, the state-of-the-art facility will serve as the company's primary East Coast research and development and technical operations hub. Construction at the 192,000-square-foot site is underway and Horizon expect

Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming virtual investor conferences: Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference: A View from the Top Tim Walbert, chairman, president and chief executive officer, will present at 9 a.m. ET on Thursday, Jan. 6, 2022. The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeut

Horizon Therapeutics plc to Participate in Upcoming Investor Conferences

Alpine Immune Sciences

SEATTLE & DUBLIN--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN) and Horizon Therapeutics plc (Nasdaq: HZNP) today announced an exclusive license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine's unique discovery platform. The overall agreement includes licensing of a lead, potential first-in-class preclinical candidate, as well as a research collaboration to jointly generate additional novel candidat

Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Horizon Therapeutics (HZNP) Down 6.6% Since Last Earnings Report: Can It Rebound?

DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today it has made a $100,000 seed donation to promote community engagement around the renovation of Emmett Till's childhood home in Chicago's West Woodlawn neighborhood. The Till-Mobley Great Migration House Museum, Theatre & Garden will focus on educating patrons about the movement of seven million Blacks from the Jim Crow south to northern cities, which they transformed through hard work and enriched with

Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till's Home into a Museum and Theater

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has been named to Great Place to Work's 2021 Best Workplaces for Parents list, which highlights companies that have created consistently positive experiences for working parents. “Horizon is proud to receive this recognition for the third year in a row, especially during the COVID-19 pandemic, which has presented parents and caregivers with unique challenges that have impacted their personal and professiona

Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced $140,000 in scholarships to help economically disadvantaged students from Trinity College Dublin and Waterford Institute of Technology cover their non-tuition expenses. The scholarships will support 12 students from Trinity College Dublin who are studying STEM (Science, Technology, Engineering and Mathematics) related programs and two students in the health sciences and accounting programs at the Waterford Institut

Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education

Amgen

AstraZeneca

Bristol-Myers

Novartis

Vertex Pharmaceuticals

Viatris

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.

7 Drug Stocks to Buy Now While They're Still on Sale

DUBLIN--(BUSINESS WIRE)--Analysis published in Multiple Sclerosis and Related Disorders supports the efficacy of UPLIZNA in NMOSD patients previously treated with rituximab.

New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)

The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder.

Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSD

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week

Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces findings of a real-world adherence analysis of TEPEZZA (teprotumumab-trbw) for the treatment of TED at AAO 2021.

New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for UPLIZNA® (inebilizumab) as a monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). UPLIZNA has been granted orphan designation by

Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon handily beat Q3 estimates and raised the full-year guidance. The beat was not enough to push the stock to new highs as investors seem accustomed to blowout quarters. But not every quarter can be a blowout quarter.

Horizon Therapeutics: Q3 Earnings Beat Not Enough For New Highs

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with diffuse cutaneous systemic sclerosis, a subset of systemic sclerosis (also known as scleroderma). Systemic sclerosis is a rare, chronic, autoimmune disease marked by fibrosis, or skin thickening, caused by excess collagen production

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the Chicago Tribune's Top Workplaces 2021, ranking No. 5 out of 75 other midsize companies in the Chicago area. This is Horizon's seventh time on the list. “We are always honored to be named to the Chicago Tribune's Top Workplaces list,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Because giving back to the communities where we live and work is foundati

Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of results from the completed PROTECT trial evaluating KRYSTEXXA® (pegloticase injection) in people with chronic gout refractory to conventional therapies, also known as uncontrolled gout, who had received a kidney transplant. In additional presentations, the company shared new insights on the challenges of gout among individuals with chronic kidney disease who undergo dialysis. These data are pres

Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q3 2021 Results - Earnings Call Transcript

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 13.64% and 5.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Top Estimates

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced Paul Hoelscher, executive vice president, chief financial officer, will retire effective May 16, 2022, and continue as an advisor to the Company through May 2023. Aaron Cox, who was named executive vice president, finance, will succeed Mr. Hoelscher. “Paul has served as Horizon's CFO since 2014 and has been critical in guiding and driving our growth,” said Tim Walbert, chairman, president and chief executive office

Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Horizon Therapeutics (HZNP) is a Top-Ranked Momentum Stock: Should You Buy?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced presentations on results from a new survey of practicing rheumatologists suggesting the presence of negative gout stigma surrounding causality and management of gout. In addition, the largest in-practice analysis to-date showing the use of KRYSTEXXA (pegloticase injection) with immunomodulation may impact treatment response rates for people living with chronic gout refractory to conventional therapies, also known a

New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon's Commitment to Improving Outcomes for People Living with Uncontrolled Gout

News for Horizon Pharma Stock (HZNP)